摘要
免疫系统在控制和根除肿瘤细胞中起着重要作用。近年,由于疗效显著,而使免疫疗法在肿瘤治疗中备受关注。自然杀伤(NK)细胞是机体固有免疫系统效应细胞,无需抗原提呈,即可识别并杀伤肿瘤细胞。随着对NK细胞杀伤肿瘤细胞作用机制的深入研究,以NK细胞为基础的血液系统肿瘤细胞免疫疗法备受关注。嵌合抗原受体T细胞(CAR-T)免疫疗法是一种特异性修饰T淋巴细胞识别靶抗原的新兴免疫疗法,随着对特异性肿瘤标志物的不断发现及基因工程技术的不断发展,CAR-T免疫疗法逐渐完善,其对血液系统恶性肿瘤的治疗也取得了新的突破。近年,免疫检查点抑制剂成为肿瘤治疗研究的新热点,其中以程序性死亡因子(PD)-l及PD配体(PD-L)1为靶点的免疫检查点抑制药物,在各类肿瘤临床试验中显示出了良好的疗效和安全性。笔者拟就细胞免疫疗法中的NK细胞、CAR-T,以及免疫检查点抑制剂PD-1及PD-L1抑制剂在免疫治疗血液系统恶性肿瘤中的研究进展进行综述。
The immune system plays an important role in controlling and eradicating tumor cells.In recent years,immunotherapy for tumor has attracted more and more attention,because of its remarkable therapeutic effect.Natural killer(NK)cells are the innate immune system effector cells of the body,which can recognize and kill tumor cells without antigen pre-sensitization.With the in-depth study of the mechanisms of NK cells killing tumor cells,the immunotherapy of tumor cells in hematologic neoplasms based on NK cells has attracted much attention.The chimeric antigen receptor T cells(CAR-T)technology is a new immunotherapy method to redirect T lymphocytes to target antigens.With the continuous discovery of specific tumor markers and the continuous development of genetic engineering technology,the CAR-T technology becomes more and more mature,and has made new breakthroughs in the treatment of hematologic neoplasms.In recent years,immunocheckpoint inhibitor immunotherapy has become a new hot spot in the treatment of hematologic neoplasms.The immunosuppressive drugs targeting programmed death(PD)-1 and PD ligand(PD-L)1 have shown good efficacy and safety in various tumor clinical trials.In this paper,research progress of NK cell therapy,CAR-T and PD-L and PD-L1 inhibitors immunotherapy in hematologic neoplasms are reviewed.
作者
雷学文
韩艳秋
Lei Xuewen;Han Yanqiu(Affiliated Hospital of Inner Mongolia Medical University,Hohhot 010000,Inner Mongolia Autonomous Region,China;Department of Hematology,Affiliated Hospital of Inner Mongolia Medical University,Affiliated Hospital of Hohhot,Hohhot 010000,Inner Mongolia Autonomous Region,China)
出处
《国际输血及血液学杂志》
CAS
2020年第2期175-180,共6页
International Journal of Blood Transfusion and Hematology
